PharmaCyte Biotech, Inc. (PMCB) stock
PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
$6.68−0.92 (-12.11%)
Close on Nov 13, 2026Market cap $71.71MP/E –Yield –
PharmaCyte Biotech r&d expenses
Research and development expenses are spending on new products and technology.
PharmaCyte Biotech's R&D Expenses for the twelve months ending Apr 30, 2026 was $391.30K, down 10.7% year over year. For fiscal 2026 it was $391.30K, down 10.7% from the year before. Over ten years it grew -12.0% a year on average. The highest annual figure on record is $3.48M in fiscal 2015.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | $391.30K | -10.7% |
| FY2025 | Apr 30, 2025 | $438.42K | +7.6% |
| FY2024 | Apr 30, 2024 | $407.43K | -13.0% |
| FY2023 | Apr 30, 2023 | $468.54K | -32.2% |
| FY2022 | Apr 30, 2022 | $690.94K | -24.6% |
| FY2021 | Apr 30, 2021 | $916.25K | +204.2% |
| FY2020 | Apr 30, 2020 | $301.22K | -34.5% |
| FY2019 | Apr 30, 2019 | $460.05K | -77.0% |
| FY2018 | Apr 30, 2018 | $2.00M | +69.0% |
| FY2017 | Apr 30, 2017 | $1.18M | -16.0% |
| FY2016 | Apr 30, 2016 | $1.41M | -59.5% |
| FY2015 | Apr 30, 2015 | $3.48M | +974.8% |
| FY2014 | Apr 30, 2014 | $323.50K | – |
| FY2013 | Apr 30, 2013 | $0 | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | $60.00K | -49.2% |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | $61.95K | -36.4% |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | $93.11K | -3.0% |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | $126.73K | +34.6% |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | $118.20K | -6.7% |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | $97.47K | +18.8% |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | $96.02K | -8.1% |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | $94.18K | +9.7% |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | $126.73K | +179.2% |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | $82.03K | -53.9% |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | $104.48K | -34.4% |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | $85.87K | -66.2% |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | $45.39K | -71.3% |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | $178.00K | +31.6% |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | $159.27K | +10.9% |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | $254.07K | -20.7% |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | $158.04K | -9.2% |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | $135.22K | -10.6% |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | $143.61K | -46.9% |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | $320.27K | +228.0% |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | $174.09K | +53.7% |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | $151.31K | +743.4% |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | $270.57K | +274.1% |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | $97.66K | +442.1% |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | $113.30K | +91.6% |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | $17.94K | -84.4% |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | $72.33K | -73.0% |
| Q4 FY2019CQ1 2019 | Apr 30, 2019 | $18.01K | -92.9% |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | $59.14K | -92.6% |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | $115.10K | -77.7% |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | $267.79K | -37.4% |
| Q4 FY2018CQ1 2018 | Apr 30, 2018 | $252.12K | +45.1% |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | $802.56K | +38.4% |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | $515.46K | +103.1% |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | $427.67K | +144.4% |
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | $173.76K | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | $579.72K | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | $253.77K | – |
| Q1 FY2017CQ2 2016 | Jul 31, 2016 | $175.00K | – |
See a number that looks wrong?